Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.
Identifieur interne : 000B90 ( PubMed/Checkpoint ); précédent : 000B89; suivant : 000B91Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.
Auteurs : Max R. O Donnell [Afrique du Sud] ; Allison Wolf ; Lise Werner ; C Robert Horsburgh ; Nesri PadayatchiSource :
- Journal of acquired immune deficiency syndromes (1999) [ 1944-7884 ] ; 2014.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Agents antiVIH (administration et posologie), Antituberculeux (administration et posologie), Enquêtes et questionnaires, Facteurs socioéconomiques, Femelle, Humains, Infections à VIH (immunologie), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Jeune adulte, Modèles logistiques, Mycobacterium tuberculosis (isolement et purification), Mâle, Observance du traitement médicamenteux, République d'Afrique du Sud, Tuberculose ultrarésistante aux médicaments (immunologie), Tuberculose ultrarésistante aux médicaments (microbiologie), Tuberculose ultrarésistante aux médicaments (traitement médicamenteux), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification), Études de cohortes, Études prospectives.
- MESH :
- administration et posologie : Agents antiVIH, Antituberculeux.
- immunologie : Infections à VIH, Tuberculose ultrarésistante aux médicaments.
- isolement et purification : Mycobacterium tuberculosis, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- microbiologie : Tuberculose ultrarésistante aux médicaments.
- traitement médicamenteux : Infections à VIH, Tuberculose ultrarésistante aux médicaments.
- virologie : Infections à VIH.
- Adolescent, Adulte, Adulte d'âge moyen, Enquêtes et questionnaires, Facteurs socioéconomiques, Femelle, Humains, Jeune adulte, Modèles logistiques, Mâle, Observance du traitement médicamenteux, République d'Afrique du Sud, Études de cohortes, Études prospectives.
- Wicri :
- geographic : Afrique du Sud.
English descriptors
- KwdEn :
- Adolescent, Adult, Anti-HIV Agents (administration & dosage), Antitubercular Agents (administration & dosage), Cohort Studies, Extensively Drug-Resistant Tuberculosis (drug therapy), Extensively Drug-Resistant Tuberculosis (immunology), Extensively Drug-Resistant Tuberculosis (microbiology), Female, HIV Infections (drug therapy), HIV Infections (immunology), HIV Infections (virology), HIV-1 (isolation & purification), Humans, Logistic Models, Male, Medication Adherence, Middle Aged, Mycobacterium tuberculosis (isolation & purification), Prospective Studies, Socioeconomic Factors, South Africa, Surveys and Questionnaires, Young Adult.
- MESH :
- chemical , administration & dosage : Anti-HIV Agents, Antitubercular Agents.
- geographic : South Africa.
- drug therapy : Extensively Drug-Resistant Tuberculosis, HIV Infections.
- immunology : Extensively Drug-Resistant Tuberculosis, HIV Infections.
- isolation & purification : HIV-1, Mycobacterium tuberculosis.
- microbiology : Extensively Drug-Resistant Tuberculosis.
- virology : HIV Infections.
- Adolescent, Adult, Cohort Studies, Female, Humans, Logistic Models, Male, Medication Adherence, Middle Aged, Prospective Studies, Socioeconomic Factors, Surveys and Questionnaires, Young Adult.
Abstract
Extensively drug-resistant tuberculosis (XDR-TB)/HIV coinfection is difficult to treat with frequent adverse drug reactions and associated with high mortality. Adherence to antiretroviral therapy (ARV) and second-line TB medications may reduce mortality, prevent amplification of drug resistance, and improve outcomes.
DOI: 10.1097/QAI.0000000000000221
PubMed: 24872138
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:24872138Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.</title><author><name sortKey="O Donnell, Max R" sort="O Donnell, Max R" uniqKey="O Donnell M" first="Max R" last="O Donnell">Max R. O Donnell</name><affiliation wicri:level="1"><nlm:affiliation>*Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY; †Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; ‡Centre for Aids Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; §Department of Epidemiology, Boston University School of Public Health, Boston, MA; and ‖University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>*Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY; †Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; ‡Centre for Aids Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; §Department of Epidemiology, Boston University School of Public Health, Boston, MA; and ‖University of KwaZulu-Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author><author><name sortKey="Wolf, Allison" sort="Wolf, Allison" uniqKey="Wolf A" first="Allison" last="Wolf">Allison Wolf</name></author><author><name sortKey="Werner, Lise" sort="Werner, Lise" uniqKey="Werner L" first="Lise" last="Werner">Lise Werner</name></author><author><name sortKey="Horsburgh, C Robert" sort="Horsburgh, C Robert" uniqKey="Horsburgh C" first="C Robert" last="Horsburgh">C Robert Horsburgh</name></author><author><name sortKey="Padayatchi, Nesri" sort="Padayatchi, Nesri" uniqKey="Padayatchi N" first="Nesri" last="Padayatchi">Nesri Padayatchi</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24872138</idno><idno type="pmid">24872138</idno><idno type="doi">10.1097/QAI.0000000000000221</idno><idno type="wicri:Area/PubMed/Corpus">001951</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001951</idno><idno type="wicri:Area/PubMed/Curation">001951</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001951</idno><idno type="wicri:Area/PubMed/Checkpoint">001951</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001951</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.</title><author><name sortKey="O Donnell, Max R" sort="O Donnell, Max R" uniqKey="O Donnell M" first="Max R" last="O Donnell">Max R. O Donnell</name><affiliation wicri:level="1"><nlm:affiliation>*Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY; †Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; ‡Centre for Aids Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; §Department of Epidemiology, Boston University School of Public Health, Boston, MA; and ‖University of KwaZulu-Natal, Durban, South Africa.</nlm:affiliation><country xml:lang="fr">Afrique du Sud</country><wicri:regionArea>*Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY; †Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; ‡Centre for Aids Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; §Department of Epidemiology, Boston University School of Public Health, Boston, MA; and ‖University of KwaZulu-Natal, Durban</wicri:regionArea><wicri:noRegion>Durban</wicri:noRegion></affiliation></author><author><name sortKey="Wolf, Allison" sort="Wolf, Allison" uniqKey="Wolf A" first="Allison" last="Wolf">Allison Wolf</name></author><author><name sortKey="Werner, Lise" sort="Werner, Lise" uniqKey="Werner L" first="Lise" last="Werner">Lise Werner</name></author><author><name sortKey="Horsburgh, C Robert" sort="Horsburgh, C Robert" uniqKey="Horsburgh C" first="C Robert" last="Horsburgh">C Robert Horsburgh</name></author><author><name sortKey="Padayatchi, Nesri" sort="Padayatchi, Nesri" uniqKey="Padayatchi N" first="Nesri" last="Padayatchi">Nesri Padayatchi</name></author></analytic><series><title level="j">Journal of acquired immune deficiency syndromes (1999)</title><idno type="eISSN">1944-7884</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Anti-HIV Agents (administration & dosage)</term><term>Antitubercular Agents (administration & dosage)</term><term>Cohort Studies</term><term>Extensively Drug-Resistant Tuberculosis (drug therapy)</term><term>Extensively Drug-Resistant Tuberculosis (immunology)</term><term>Extensively Drug-Resistant Tuberculosis (microbiology)</term><term>Female</term><term>HIV Infections (drug therapy)</term><term>HIV Infections (immunology)</term><term>HIV Infections (virology)</term><term>HIV-1 (isolation & purification)</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Medication Adherence</term><term>Middle Aged</term><term>Mycobacterium tuberculosis (isolation & purification)</term><term>Prospective Studies</term><term>Socioeconomic Factors</term><term>South Africa</term><term>Surveys and Questionnaires</term><term>Young Adult</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Agents antiVIH (administration et posologie)</term><term>Antituberculeux (administration et posologie)</term><term>Enquêtes et questionnaires</term><term>Facteurs socioéconomiques</term><term>Femelle</term><term>Humains</term><term>Infections à VIH (immunologie)</term><term>Infections à VIH (traitement médicamenteux)</term><term>Infections à VIH (virologie)</term><term>Jeune adulte</term><term>Modèles logistiques</term><term>Mycobacterium tuberculosis (isolement et purification)</term><term>Mâle</term><term>Observance du traitement médicamenteux</term><term>République d'Afrique du Sud</term><term>Tuberculose ultrarésistante aux médicaments (immunologie)</term><term>Tuberculose ultrarésistante aux médicaments (microbiologie)</term><term>Tuberculose ultrarésistante aux médicaments (traitement médicamenteux)</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (isolement et purification)</term><term>Études de cohortes</term><term>Études prospectives</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Anti-HIV Agents</term><term>Antitubercular Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>South Africa</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Agents antiVIH</term><term>Antituberculeux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Extensively Drug-Resistant Tuberculosis</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Infections à VIH</term><term>Tuberculose ultrarésistante aux médicaments</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Extensively Drug-Resistant Tuberculosis</term><term>HIV Infections</term></keywords><keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en"><term>HIV-1</term><term>Mycobacterium tuberculosis</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Mycobacterium tuberculosis</term><term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Tuberculose ultrarésistante aux médicaments</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Extensively Drug-Resistant Tuberculosis</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term><term>Tuberculose ultrarésistante aux médicaments</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>HIV Infections</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Cohort Studies</term><term>Female</term><term>Humans</term><term>Logistic Models</term><term>Male</term><term>Medication Adherence</term><term>Middle Aged</term><term>Prospective Studies</term><term>Socioeconomic Factors</term><term>Surveys and Questionnaires</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enquêtes et questionnaires</term><term>Facteurs socioéconomiques</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Modèles logistiques</term><term>Mâle</term><term>Observance du traitement médicamenteux</term><term>République d'Afrique du Sud</term><term>Études de cohortes</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Afrique du Sud</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Extensively drug-resistant tuberculosis (XDR-TB)/HIV coinfection is difficult to treat with frequent adverse drug reactions and associated with high mortality. Adherence to antiretroviral therapy (ARV) and second-line TB medications may reduce mortality, prevent amplification of drug resistance, and improve outcomes.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24872138</PMID><DateCreated><Year>2014</Year><Month>08</Month><Day>13</Day></DateCreated><DateCompleted><Year>2015</Year><Month>01</Month><Day>13</Day></DateCompleted><DateRevised><Year>2017</Year><Month>02</Month><Day>20</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1944-7884</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>1</Issue><PubDate><Year>2014</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of acquired immune deficiency syndromes (1999)</Title><ISOAbbreviation>J. Acquir. Immune Defic. Syndr.</ISOAbbreviation></Journal><ArticleTitle>Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.</ArticleTitle><Pagination><MedlinePgn>22-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/QAI.0000000000000221</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Extensively drug-resistant tuberculosis (XDR-TB)/HIV coinfection is difficult to treat with frequent adverse drug reactions and associated with high mortality. Adherence to antiretroviral therapy (ARV) and second-line TB medications may reduce mortality, prevent amplification of drug resistance, and improve outcomes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Prospective cohort study of XDR-TB patients on treatment in KwaZulu-Natal, South Africa. Adherence to ARV and TB medications was assessed separately at baseline and monthly. Knowledge, attitudes, and beliefs were assessed at baseline. Optimal adherence was defined as self-report of taking all pills in the previous 7 days; missing any pills was defined as suboptimal adherence. Primary outcome was optimal adherence 6 months after initiation of XDR-TB treatment to TB medications, ARV, and both ("dual adherence").</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">One hundred four XDR-TB patients (79.8% HIV coinfected, 84.3% on ARV at enrollment) were enrolled and followed monthly (median 8 visits; interquartile range: 4-12). Six-month optimal adherence was higher for ARV (88.2%) than TB medications (67.7%) (P < 0.001). Low educational attainment, male gender, and year of enrollment were independently associated with dual suboptimal adherence. At baseline, participants indicated that XDR-TB was curable (76.0%), HIV and TB were linked (81.7%), and ARV improves TB outcomes (72.1%). Baseline knowledge, attitudes, and beliefs did not predict subsequent adherence.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Medication adherence was significantly higher for ARV than for TB medications in this cohort. Short-course treatment regimens for drug-resistant TB with lower pill burden may increase adherence and improve outcomes in XDR-TB/HIV. Programmatic support for dual adherence is critical in the treatment of drug-resistant TB and HIV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>OʼDonnell</LastName><ForeName>Max R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>*Division of Pulmonary, Allergy and Critical Care Medicine, Columbia University Medical Center, New York, NY; †Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY; ‡Centre for Aids Program of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa; §Department of Epidemiology, Boston University School of Public Health, Boston, MA; and ‖University of KwaZulu-Natal, Durban, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Allison</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Werner</LastName><ForeName>Lise</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Horsburgh</LastName><ForeName>C Robert</ForeName><Initials>CR</Initials></Author><Author ValidYN="Y"><LastName>Padayatchi</LastName><ForeName>Nesri</ForeName><Initials>N</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 AI098479</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5K23AI098479</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Acquir Immune Defic Syndr</MedlineTA><NlmUniqueID>100892005</NlmUniqueID><ISSNLinking>1525-4135</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019380">Anti-HIV Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CitationSubset>X</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2009 Jul;13(7):855-61</RefSource><PMID Version="1">19555535</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Emerg Infect Dis. 2013 Mar;19(3):416-24</RefSource><PMID Version="1">23622055</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2014 Apr 5;383(9924):1230-9</RefSource><PMID Version="1">24439237</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Am J Respir Crit Care Med. 2010 Jan 1;181(1):80-6</RefSource><PMID Version="1">19833824</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Behav. 2013 Jan;17(1):284-97</RefSource><PMID Version="1">22407465</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2007 Jul 24;4(7):e238</RefSource><PMID Version="1">17676945</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Health Serv Res. 2009;9:169</RefSource><PMID Version="1">19765290</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mult Scler. 2009 Mar;15(3):316-22</RefSource><PMID Version="1">19153173</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Behav. 2006 May;10(3):227-45</RefSource><PMID Version="1">16783535</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Public Health. 2012;12:56</RefSource><PMID Version="1">22264339</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2013;8(5):e63057</RefSource><PMID Version="1">23667572</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Tuberculosis (Edinb). 2008 Aug;88 Suppl 1:S85-92</RefSource><PMID Version="1">18762156</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2000 Jun;12(3):255-66</RefSource><PMID Version="1">10928201</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS. 2008 Jan 2;22(1):75-82</RefSource><PMID Version="1">18090394</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Public Health. 2013;13:396</RefSource><PMID Version="1">23622516</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Public Health. 2010;10:651</RefSource><PMID Version="1">21029405</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2010 May 22;375(9728):1798-807</RefSource><PMID Version="1">20488525</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Care. 2011 May;23(5):601-11</RefSource><PMID Version="1">21293992</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Arch Psychiatry Clin Neurosci. 2014 Mar;264(2):93-102</RefSource><PMID Version="1">23880959</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur Respir J. 2009 May;33(5):1085-94</RefSource><PMID Version="1">19164345</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2012;7(1):e29186</RefSource><PMID Version="1">22235271</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 2000 May 17;283(19):2537-45</RefSource><PMID Version="1">10815117</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2004 Mar 6;363(9411):814-9</RefSource><PMID Version="1">15016493</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>AIDS Behav. 2011 Oct;15(7):1381-96</RefSource><PMID Version="1">21468660</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Clin Pharmacol. 2010;10:11</RefSource><PMID Version="1">20849595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Nov 4;368(9547):1575-80</RefSource><PMID Version="1">17084757</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Epidemiol. 2002 Feb;31(1):37-40</RefSource><PMID Version="1">11914290</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMJ. 2008 Mar 1;336(7642):484-7</RefSource><PMID Version="1">18250104</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2005 Mar;9(3):263-9</RefSource><PMID Version="1">15786888</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>BMC Public Health. 2011;11:916</RefSource><PMID Version="1">22151609</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Intern Med. 2000 Jul 4;133(1):21-30</RefSource><PMID Version="1">10877736</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tuberc Lung Dis. 2010 Apr;14(4):454-63</RefSource><PMID Version="1">20202304</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>ISRN Pharmacol. 2012;2012:274978</RefSource><PMID Version="1">22530137</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Med Health Sci Res. 2013 Jan;3(1):67-74</RefSource><PMID Version="1">23634333</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Infect Dis. 2013 Jul;208(1):40-9</RefSource><PMID Version="1">23204161</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Emerg Infect Dis. 2013 Mar;19(3):449-55</RefSource><PMID Version="1">23622714</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2006 Oct 1;43(7):939-41</RefSource><PMID Version="1">16941380</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS Med. 2012;9(8):e1001300</RefSource><PMID Version="1">22952439</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>JAMA. 1999 Mar 24-31;281(12):1069</RefSource><PMID Version="1">10188643</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Infect Dis. 2002 Apr 15;34(8):1115-21</RefSource><PMID Version="1">11915001</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2011;6(1):e15841</RefSource><PMID Version="1">21253585</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019380" MajorTopicYN="N">Anti-HIV Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054908" MajorTopicYN="N">Extensively Drug-Resistant Tuberculosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055118" MajorTopicYN="Y">Medication Adherence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009169" MajorTopicYN="N">Mycobacterium tuberculosis</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012959" MajorTopicYN="N">Socioeconomic Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013019" MajorTopicYN="N" Type="Geographic">South Africa</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">NIHMS594209</OtherID><OtherID Source="NLM">PMC4410008</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>5</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24872138</ArticleId><ArticleId IdType="doi">10.1097/QAI.0000000000000221</ArticleId><ArticleId IdType="pmc">PMC4410008</ArticleId><ArticleId IdType="mid">NIHMS594209</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Afrique du Sud</li></country></list><tree><noCountry><name sortKey="Horsburgh, C Robert" sort="Horsburgh, C Robert" uniqKey="Horsburgh C" first="C Robert" last="Horsburgh">C Robert Horsburgh</name><name sortKey="Padayatchi, Nesri" sort="Padayatchi, Nesri" uniqKey="Padayatchi N" first="Nesri" last="Padayatchi">Nesri Padayatchi</name><name sortKey="Werner, Lise" sort="Werner, Lise" uniqKey="Werner L" first="Lise" last="Werner">Lise Werner</name><name sortKey="Wolf, Allison" sort="Wolf, Allison" uniqKey="Wolf A" first="Allison" last="Wolf">Allison Wolf</name></noCountry><country name="Afrique du Sud"><noRegion><name sortKey="O Donnell, Max R" sort="O Donnell, Max R" uniqKey="O Donnell M" first="Max R" last="O Donnell">Max R. O Donnell</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/SidaSubSaharaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B90 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000B90 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= SidaSubSaharaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:24872138
|texte= Adherence in the treatment of patients with extensively drug-resistant tuberculosis and HIV in South Africa: a prospective cohort study.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:24872138" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SidaSubSaharaV1
| This area was generated with Dilib version V0.6.32. |  |